May 2, 2025 03:29 PM EDTUpdated 03:48 PM
R&D
Cell/Gene Tx

Ex­clu­sive: Ver­tex drops AAV gene ther­a­py re­search, tR­NA ther­a­py part­ner­ship

Ryan Cross

Senior Science Correspondent

Ver­tex is pulling back on its ge­net­ic med­i­cine re­search, end­ing all work re­lat­ed to ade­no-as­so­ci­at­ed virus­es, or AAVs — the vi­ral vec­tors com­mon­ly used to de­liv­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Drug­mak­ers ex­ploit can­cer’s ‘lethal­i­ties’ to make next class of tar­get­ed ther­a­pies, with first re­sults for ...

Ex­clu­sive: Af­ter FDA fir­ings, drug re­view­ers are asked to vol­un­teer for ad­min­is­tra­tive work

The in­side sto­ry of how Sali­o­Gen, a start­up try­ing to wran­gle ‘jump­ing genes’ to make med­i­cines, fell apart

Feng Zhang’s pro­tein nanopar­ti­cle start­up Aera Ther­a­peu­tics turns to lipid nanopar­ti­cles to jump­start its pipeline

White House bud­get re­quest would cut bil­lions at NIH and CDC, add $500M for MA­HA

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times